Drug Approval | December 17, 2023
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The product is expected to be launched in FY25
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Clindamycin Phosphate Gel is used to treat acne
The products will be manufactured at the company's facility in Bengaluru
The approval bolsters the company's Mycophenolate Mofetil portfolio
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
The product is being launched in August 2023
Subscribe To Our Newsletter & Stay Updated
